Research Projects & Grants

For Profit Organization

  • A Randomized, Double-blind, Placebo-controlled Multicenter Study to Assess the Efficacy and Safety of Lenrispodun as Adjunctive Therapy in the Treatment of Patients with Motor Fluctuations due to Parkinson's Disease. Protocol: ITI-214-202, Role: Investigator, Intra-Cellular Therapies, Inc, (04/2024 - 04/2025) Status: Approved
  • A Multicenter Phase 2, Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants with Advanced Parkinson's Disease. PD0060, Role: Investigator, UCB Biopharma SPRL, (03/2024 - 03/2025) Status: Approved
  • A Phase I, Randomized, Open-Label, Active Controlled, Multi-Center Pilot Study to Compare Reference to Reference Pharmacodynamics of BOTOX® (onabotulinumtoxinA) in Healthy Subjects. Protocol: MR 103A-0I-IPS-1001. lnformed Consent Form Version Dated 25 November 2022., Role: Investigator, Mylan Pharmaceuticals, (11/2023 - 03/2024) Status: Completed
  • An Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Repeat Intramuscular ABP-450 (prabotulinumtoxinA) Injection for the Treatment of Cervical Dystonia. Protocol Number: ABP-19002, Role: Investigator, Aeon Biopharma, (12/2022 - 12/2023) Status: Completed
  • RESTORE: A clinical study of patients with symptomatic neuRogenic orthostatic hypotEnsion assess sustained effecTs of dRoxidopa therapy, Role: Investigator, Lundbeck Inc., (02/2022 - 02/2023) Status: Completed
  • A phase 3, open-label study of the safety, efficacy, and tolerability of apomorphine administered by continuous subcutaneous infusion in advanced Parkinson's disease patients with unsatisfactory control on available therapy, Role: PI, U.S. World Meds, (11/2021 - 11/2022) Status: Completed
  • A Phase 3, open-label, multi-center trial to evaluate the long-term safety and efficacy of repeat treatment of DaxibotulinumtoxinA for injection in adult with isolated cervical dystonia (ASPEN-OLS). Protocol: 1720304, Role: Investigator, Revance Therapeutics, Inc., (04/2021 - 04/2022) Status: Completed
  • A Phase 3, randomized, double-blind, placebo-controlled, parallel group, multi-center trial to evaluate the efficacy and safety of a single treatment of DaxibotulinumtoxinA for injection in adults with isolated cervical dystonia (ASPEN-1). Protocol: 1720302, Role: PI, Revance Therapeutics, Inc., (11/2019 - 11/2020) Status: Completed
  • Evaluation of the safety and pharmacodynamic effect of AGN-151607 by measuring the compound muscle action potential (CMAP) of the extensor digitorum brevis ( EDB) muscle following a single injection in healthy subjects. Protocol 1925-101-008, dated 18 August 2017. Informed consent form version dated 30 August 2017, Role: Investigator, Allergan Inc., (08/2018 - 08/2019) Status: Completed
  • A 12-month, dose-level blinded study investigating the safety and efficacy of CVT-301 (Levodopa inhalation powder) in Parkinson's Disease patients with motor response fluctuations (off phenomena). protocol number: CVT-301-004E, Role: Investigator, Civitas Therapeutics, Inc., (03/2018 - 03/2019) Status: Completed
  • ASPIRE: Adult spasticity international registry on BOTOX treatment, Role: Investigator, Allergan Inc., (10/2017 - 10/2018) Status: Completed
  • A phase 3, multicenter, randomized, double-blinded, placebo controlled study with an open label phase to determine the efficacy and safety of tozadenant as adjunctive therapy in levodopa-treated patients with Parkinson's Disease experiencing end of dose "wearing off" (TOZ-PD). Protocol #: TOZ-CL05, Role: Investigator, Biotie Therapies Inc, (07/2017 - 07/2018) Status: Completed
  • A phase 3, long-term, open-label and single-arm study of MYOBLOC® in the treatment of troublesome sialorrhea in adult subjects. Protocol Number: SN-SIAL-351, Role: Investigator, U.S. World Meds, (03/2017 - 03/2018) Status: Completed
  • A phase 3, multi-center, double-blind, placebo-controlled, single-treatment efficacy and safety study of MYOBLOC® (Part A) followed by open-label, multiple-treatment with MYOBLOC® (Part B) in the treatment of troublesome Sialorrhea in adult subjects. Protocol number: SN-SIAL-301, Role: Investigator, U.S. World Meds, (12/2016 - 12/2017) Status: Completed
  • A phase 3, randomized, double-blind, placebo-controlled study investigating the efficacy and safety of CVT-301 (Levodopa inhalation powder) in Parkinson's Disease patients with motor response fluctuations (OFF Phenomena). (SPAN-PD TM), Role: Investigator, Civitas Therapeutics, Inc., (12/2016 - 12/2017) Status: Completed
  • An open-label, non-inferiority study evaluating the efficacy and safety of two injection schedules of xeomin (incobotulinumtoxinA) [short flex vs. long flex] in subjects with cervical Dystonia with < 10 weeks of benefit from onabotulinumtoxinA treatment. Protocol #MUS 60201 4073 1 dated 01Sep2011. Informed consent version dated 23Nov2011., Role: Investigator, Merz Pharmaceuticals, LLC, (01/2016 - 01/2017) Status: Completed
  • A phase IIIb, prospective, multicentre, open-label extension study to assess long term safety and effectiveness of Dysport® using 2 mL dilution in adults with cervical dystonia. Protocol A-TL-52120-170, Role: Investigator, Ipsen Biopharmaceuticals, Inc., (03/2015 - 03/2016) Status: Completed
  • A phase IIIb, multicentre, randomised, double-blind, placebo-controlled study evaluating the efficacy and safety of Dysport® using 2 mL dilution in adults with cervical dystonia. Protocol A-TL-52120-169, Role: Investigator, Ipsen Biopharmaceuticals, Inc., (03/2015 - 03/2016) Status: Completed
  • A Multicenter, Interventional, Post-marketing, Randomized, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport®) in Comparison with OnabotulinumtoxinA (Botox®) when Treating Adults with Upper Limb Spasticity. Protocol: CLIN-52120-452, Role: Investigator, Ipsen Pharma SAS, (11/2024 - 11/2025) Status: Approved

Internal

  • The development of oculomotor abnormalities in Parkinson's Disease, Role: PI, LLU Dept. of Neurology, (12/2024 - 12/2025) Status: Approved
  • MRI Evidence of Increased Iron Deposition in the Basal Ganglia of Patients Admitted for Stroke with a History of Methamphetamine Use: A Prevalence Study, Role: PI, LLU Dept. of Neurology, (09/2023) Status: Approved
  • Correlation of spirituality and Parkinson's disease, Role: Investigator, LLU Dept. of Neurology, (05/2023) Status: Approved
  • Access to Opicapone and Istradefylline in adult patients with Parkinson's disease, Role: Investigator, LLU Dept. of Pharmacy Practice, (10/2022) Status: Approved
  • Evaluation of Risk Factors for Development of Drug-Induced Parkinsonism (DIP), Role: Investigator, LLU Dept. of Pharmacy Practice, (10/2022) Status: Approved
  • Does cannabis induce psychosis in Parkinson's disease patients?, Role: PI, LLU Dept. of Neurology, (02/2019 - 09/2024) Status: Completed

Non-Profit Organization

  • An Open-Label Extension of Studies M15-736 and M20-339 to Evaluate the Safety and Tolerability Of 24-Hour Daily Exposure of ABBV-951 in Subjects with Advanced Parkinson's Disease, Role: Investigator, AbbVie, Inc., (09/2024 - 09/2025) Status: Approved
  • A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study of BOTOX® for the Treatment of Upper Limb Essential Tremor. Protocol: M21-471, Role: Investigator, AbbVie, Inc., (09/2024 - 09/2025) Status: Approved
  • A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study Comparing the Efficacy, Safety and Tolerability of ABBV-951 to Oral Carbidopa/Levodopa in Advanced Parkinson’s Disease Patients. Protocol: M15-736, Role: Investigator, AbbVie, Inc., (02/2021 - 02/2022) Status: Completed